Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm
Status:
Not yet recruiting
Trial end date:
2029-06-30
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-centre, single-arm study assessing the efficacy and safety of
osimertinib as adjuvant treatment in stage IB-IIIB (8th AJCC) NSCLC with uncommon EGFRm after
receiving complete surgical resection with or without adjuvant chemotherapy.